liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Long-term outcomes of left ventricular assist device therapy in Scandinavia
Karolinska University, Stockholm, Sweden.
Copenhagen University, Copenhagen, Denmark.
Copenhagen University, Copenhagen, Denmark.
Sahlgrenska Academy, Göteborg, Sweden.
Show others and affiliations
2014 (English)In: The Journal of Hearth and Lung Transplantation, Vol. 33, no 4, s216- p.Article in journal (Refereed) Published
Abstract [en]

Purpose

The purpose was to assess outcomes with durable continuous-flow left ventricular assist device (LVAD) in Scandinavia.

Methods

Since 1993, 497 durable LVADs have been implanted among 9 centers in Scandinavia. Of those, 273 were 2nd and 3rd generation LVAD, 80% as bridge to transplant. We performed a retrospective analysis of 252 patients with complete data. Postoperative complications and survival, with censorship at transplantation, were compared between groups and Cox proportion hazard regression analysis was used to identify factors associated with reduced long-term survival.

Results

The actuarial survival rate was 71%, 64% and 62% at 1 year, 3 years and 5 years respectively and similar for 2nd and 3rd generation LVADs (Figure). The most common complication were drive line infection (24%), right heart failure (24%), gastrointestinal bleeding (11%), pump thrombosis (9%) and thromboembolic events (8%) (Table), again similar for 2nd and 3rd generations LVADs. Univariable predictors of mortality were higher age, creatinine, bilirubin and lower platelet count and pulmonary vascular resistance.

Conclusion

Prognosis after continuous flow LVAD in Scandinavia is modest. Careful selection considering markers of renal insufficiency and liver congestion as well as previously reported risk markers may improve the risk / benefit ratio.

Place, publisher, year, edition, pages
2014. Vol. 33, no 4, s216- p.
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-114087DOI: 10.1016/j.healun.2014.01.558OAI: oai:DiVA.org:liu-114087DiVA: diva2:786933
Conference
The Journal of Heart and Lung Transplantation
Available from: 2015-02-07 Created: 2015-02-07 Last updated: 2015-03-31Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Hübbert, Laila

Search in DiVA

By author/editor
Hübbert, Laila
By organisation
Division of Cardiovascular MedicineFaculty of Health SciencesDepartment of Cardiology in Linköping
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 94 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf